Company intelligence / Profile preview

Primaa

Ownership: Private
Employees: ~35
Development stage: Commercial

Overview

Primaa has developed and clinically validated several AI-powered digital pathology tools that assist pathologists in the automated detection and grading of various cancers. Their Cleo Breast Tool is undergoing clinical trials to advance breast cancer detection. Published studies demonstrate improved speed and accuracy in diagnosing invasive carcinomas using their technology[1].

Therapeutic areas: Oncology
Modalities: Device (AI-powered software platform)Non-pharmacological therapy (digital pathology/diagnostic tool)
Industry: Pathology

Partnerships

Gestalt Diagnostics – collaboration to revolutionize skin cancer detectionTrusted by leading organizations/pathology labs/hospitals [implied from website]

Beyond the preview

Go deeper on Primaa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primaa.

Explore the full profile